Kari Kendra

Kari Kendra

Oncology

2050 Kenny Rd
Columbus, OH 43221

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 92 publications

Pre-treatment T-cell Transcriptional Signatures Predict Immunotherapy Outcomes in Melanoma.

Pre-treatment T-cell Transcriptional Signatures Predict Immunotherapy Outcomes in Melanoma.

Journal: Research square

Published: September 03, 2026

Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy.

Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy.

Journal: JCO oncology practice

Published: June 23, 2026

Melanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.

Melanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: June 15, 2026

How the Ketogenic Diet Shapes the Microbiome to Influence Cancer Immunotherapy Outcomes: An Exploration of Clinical Trials and Their Results.

How the Ketogenic Diet Shapes the Microbiome to Influence Cancer Immunotherapy Outcomes: An Exploration of Clinical Trials and Their Results.

Journal: Nutrition and cancer

Published: May 04, 2026

CRE26-065: Second-Line Treatments for Patients With Cemiplimab-Refractory Cutaneous Squamous Cell Carcinomas: A Brief Report.

CRE26-065: Second-Line Treatments for Patients With Cemiplimab-Refractory Cutaneous Squamous Cell Carcinomas: A Brief Report.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 16, 2026

CRE26-065: Second-Line Treatments for Patients With Cemiplimab-Refractory Cutaneous Squamous Cell Carcinomas: A Brief Report.

CRE26-065: Second-Line Treatments for Patients With Cemiplimab-Refractory Cutaneous Squamous Cell Carcinomas: A Brief Report.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 30, 2026

Vaginal Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.

Vaginal Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 13, 2026

Five-year survival with tebentafusp in metastatic uveal melanoma.

Five-year survival with tebentafusp in metastatic uveal melanoma.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: March 02, 2026

Cervical Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.

Cervical Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: February 11, 2026

Association between obesity, sex, medical comorbidities, and survival in cancer patients treated with immune checkpoint inhibitors.

Association between obesity, sex, medical comorbidities, and survival in cancer patients treated with immune checkpoint inhibitors.

Journal: Journal of Cancer

Published: December 16, 2025

Impact of proton pump inhibitors on immunotherapy is modulated by prior chemotherapy and linked to gut microbiome-immune cell signatures.

Impact of proton pump inhibitors on immunotherapy is modulated by prior chemotherapy and linked to gut microbiome-immune cell signatures.

Journal: Cancer immunology, immunotherapy : CII

Published: December 02, 2025

Early Changes in Lymphocyte/Monocyte Ratio on Treatment as a Prognostic Marker to Predict Overall Survival in Patients with Advanced Cancer Treated with Immune Checkpoint Inhibitors.

Early Changes in Lymphocyte/Monocyte Ratio on Treatment as a Prognostic Marker to Predict Overall Survival in Patients with Advanced Cancer Treated with Immune Checkpoint Inhibitors.

Journal: Cancer investigation

Published: October 10, 2025

Showing 1-12 of 92

Last Updated: 09/26/2026